
Claims

1. A compound of formula (I) which is



(I)

in acetate salt form.

2. A compound according to claim 1 which is (*R*)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in acetate salt form.

3. A crystalline form of (*R*)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

4. A crystalline form according to claim 3, characterized by an X-ray powder diffraction pattern comprising three peaks having angle of refraction 2 theta (θ) values selected from 8.8 ± 0.2°, 16.4 ± 0.2°, 20.8 ± 0.2° when measured using CuK_α radiation.

5. A crystalline form of the acetate salt of (*R*)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one which has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 6 when measured using CuK_α radiation.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1 to 5 and one or more pharmaceutically acceptable carriers.

7. A combination comprising a therapeutically effective amount of a compound according to any of claims 1 to 5 and one or more therapeutically active co-agents.

8. A method of treatment or prevention of muscular dystrophy, disuse-related atrophy, cachexia or sarcopenia comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 5 to a subject in need thereof.


9. A compound according to any of claims 1 to 5 for use as a medicament.

10. A compound according to any of claims 1 to 5 for use in the treatment or prevention of muscular dystrophy, disuse-related atrophy, cachexia or sarcopenia.

11. Use of a compound according to any of claims 1 to 5 in the manufacture of a medicament for the treatment or prevention of muscular dystrophy, disuse-related atrophy, cachexia or sarcopenia.

12. A process for the manufacture of a compound of formula (I) in acetate salt form which includes the steps of:

    a. the reaction of a compound of formula (IIa) in free form or in pharmaceutically acceptable salt form



(IIa)

    in which R_a and R_b are protecting groups with 2-(4-butoxy-phenyl)-1,1-dimethyl-ethylamine;

    b. the cleavage of any protecting groups still present;

    c. the recovery of the so obtainable compound of formula (I) in acetate salt form.

CLAIMS:

1. A crystalline form of *(R)*-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

2. A crystalline form according to claim 1, characterized by an X-ray powder diffraction pattern comprising three peaks having angle of refraction 2 theta (θ) values selected from 8.8 ± 0.2°, 16.4 ± 0.2°, 20.8 ± 0.2° when measured using CuK_α radiation.

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1 or 2 and one or more pharmaceutically acceptable carriers.

4. A combination comprising a therapeutically effective amount of a compound according to any of claims 1 or 2 and one or more therapeutically active co-agents.

5. A compound according to any of claims 1 or 2 for use as a medicament.

6. A compound according to any of claims 1 or 2 for use in the treatment or prevention of muscle-wasting diseases.

7. A compound according to claim 6, wherein the muscle wasting disease is selected from muscular dystrophy, disuse-related atrophy, cachexia or sarcopenia.